Intellia Therapeutics competitors

Intellia Therapeutics's competitors include Nightstar Therapeutics, Ultragenyx Pharmaceutical, ARCA biopharma and Lexicon Pharmaceuticals
Add company...
Intellia Therapeutics
Intellia is developing therapeutic products to help people with genetic diseases.
Nightstar Therapeutics
Nightstar Therapeutics is a clinical-stage gene therapy company, focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases.
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases.
ARCA biopharma
ARCA biopharma develops genetically-targeted therapies for cardiovascular diseases.
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals develops therapeutic products for diseases relating to immunology, metabolism, cardiology and ophthalmology.
Founding Date
Founding Date
2014
Founding Date
2013
Founding Date
2010
Founding Date
2009
Founding Date
1995
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Cambridge, US HQ
Locations
London, GB HQ
Lexington, US
Locations
Novato, US HQ
Locations
Westminster, US HQ
Aurora, US
Westminster, US
Locations
Spring, US HQ
Jersey, JE
Orlando, US
Chicago, US
The Woodlands, US
Boston, US
Indianapolis, US
see more
Employees
Employees
10470% increase
Employees
2323% decrease
Employees
376
Employees
20
Employees
168
Valuation ($)
Valuation ($)
1.2 b
Valuation ($)
430 m
Valuation ($)
4.2 b
Valuation ($)
7.4 m
Valuation ($)
1.4 b
Twitter followers
Twitter followers
2.2 k
Twitter followers
115
Twitter followers
N/A
Twitter followers
N/A
Twitter followers
108

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
N/A
Revenue (est.)
$133k (FY, 2016)
Revenue (est.)
N/A
Revenue (est.)
$90.3m (FY, 2017)
Net income
Net income
($10.6b) (FY, 2016)
Net income
($12.2m) (FY, 2016)
Net income
($245.9m) (FY, 2016)
Net income
($18.5m) (FY, 2017)
Net income
N/A

Funding

Total funding raised
Total funding raised
N/A
Total funding raised
$ 99.6m
Total funding raised
$ 200.1m
Total funding raised
$ 7.2m
Total funding raised
$ 244.7m
For sources of this data, please see the company profileDownload Excel

View company profiles

Nightstar Therapeutics
HQ
London, GB
Employees
23↓ 23% decrease

Nightstar Therapeutics is a clinical-stage gene therapy company, focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases.

View company
Ultragenyx Pharmaceutical
HQ
Novato, US
Employees
376

Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases.

View company
ARCA biopharma
HQ
Westminster, US
Employees
20

ARCA biopharma develops genetically-targeted therapies for cardiovascular diseases.

View company
Lexicon Pharmaceuticals
HQ
Spring, US
Employees
168

Lexicon Pharmaceuticals develops therapeutic products for diseases relating to immunology, metabolism, cardiology and ophthalmology.

View company